Tiotropium: a potential replacement for ipratropium in patients with COPD.
Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD). There is some evidence that tiotropium 18 micro g once daily is more efficacious than ipratropium bromide 40 micro g four times daily, for patients with COPD, as measured by improvements in lung function, dyspnea disease-specific quality of life and reductions in hospitalization due to COPD. Dry mouth is a more frequent problem with tiotropium than with ipratropium bromide.
Vijay K
VK
Shukla
D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002170:Canada; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D017277:Drug Approval; D005060:Europe; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008800:Mexico; D009520:New Zealand; D010679:Philippines; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018154:Slovakia; D013673:Technology Assessment, Biomedical; D014481:United States; D014486:United States Food and Drug Administration
D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D009241:Ipratropium